

PHARMACOLOGICAL INNOVATIONS AND NEUROSCIENCES IN HEALTHCARE

Dra. Clara Teixeira Cardoso

Prof. André Luiz Ferreira

Biofarma Integrated Dementia Research Unit

Summary

This article addresses emerging innovations in pharmacological treatments, exploring their intersection with neuroscientific discoveries. We analyze the impact of these innovations on nursing practices and public health policies, emphasizing the need for adaptation in professional training and healthcare systems to maximize benefits for the population. We discuss contemporary challenges such as drug resistance, the increasing need for holistic approaches in patient care, and the utilization of technology for monitoring and interventions.

Keywords: Innovations, Pharmacology, Neurosciences

Pharmacological Innovations: A Current Overview

New Drugs and Emerging Therapies

In recent years, the field of pharmacology has witnessed the emergence of new therapies that are transforming the treatment of neuropsychiatric disorders. Aducanumab, a monoclonal antibody used in Alzheimer's disease, stands out in this context. The administration of this drug aims to reduce beta-amyloid plaques in the brain, which are typical markers of the disease. A study conducted by Sevigny et al. (2016) demonstrated that 22% of treated patients showed significant cognitive improvement compared to the placebo group.



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)



[10.59087/biofarma.v4i1.35](https://doi.org/10.59087/biofarma.v4i1.35)

Although the efficacy has sparked debate, the introduction of aducanumab represents a significant step forward in dementia treatment. However, diagnosis must be approached with caution, as pointed out by Souza and Menegucci (2023), “clinical decisions about what to do next with a patient rely heavily on clinical judgment.” They emphasize that, when dealing with dementia cases, a thorough assessment is crucial, so that one does not rely solely on tests and examinations that often fail to provide an accurate diagnosis in living patients. According to their observations, “it is important to move towards confirmation through laboratory tests and imaging, which will help in identifying treatable causes.” This approach highlights the need for informed clinical decisions that also consider factors influencing patient expectations and daily life. Another area of innovation is the use of NMDA receptor antagonists, such as ketamine, which have shown efficacy in patients with treatment-resistant depression. A clinical trial published in the American Journal of Psychiatry indicated that up to 70% of participants experienced relief from depressive symptoms after a single infusion of ketamine (Zanos et al., 2018). Literature research shows a broad movement toward personalized treatments, considering individual genetic variability of patients.

Side Effects and Considerations

With the introduction of new drugs, concerns arise about side effects and long-term safety. The administration of innovative medications may result in adverse reactions that were not fully understood during clinical trials, highlighting the need for ongoing surveillance post-approval. Ketamine, for instance, while effective, is associated with significant side



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)



effects such as dissociation and elevated blood pressure, necessitating caution in administering the treatment (Zanos et al., 2018). Furthermore, drug resistance is a significant issue in treating psychiatric conditions. A study published in JAMA Psychiatry found that about 30% of patients with depression do not adequately respond to multiple classes of antidepressants (Fava & Davidson, 1996). Additionally, as emphasized by Souza and Menegucci (2023), in cases of Alzheimer's disease, clinical judgment must include treatment expectations, as “the available and approved medications and the expected outcome thereof” are key considerations in establishing a care plan. Such challenges underscore the importance of long-term, systematic follow-up of patients receiving innovative treatments. This not only optimizes the use of these medications but also allows for the collection of valuable data for future investigations. Therefore, a multidisciplinary approach is essential, involving pharmacists, physicians, mental health professionals, and nurses, to ensure all dimensions of care are addressed.

Drug Resistance: A Contemporary Challenge

Drug resistance is a growing concern affecting both pharmacology and clinical practice. In psychiatry, this resistance can arise from a variety of factors, including genetics, adverse side effects, and social factors influencing treatment adherence. Treatment resistance is not limited to traditional drugs; innovative treatments, including biological therapies, will also face this barrier (McIntyre RS et al., 2023). Drug resistance may also be exacerbated by the lack of accurate and timely diagnosis. Unfortunately, as medical literature indicates, we still lack effective means to make an accurate Alzheimer's disease diagnosis except through



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)



post-mortem brain tissue collection. While cognitive assessment is part of the diagnostic process, authors like Souza and Menegucci (2023) highlight that “clinical decision-making about what to do next with a patient relies much more on clinical judgment.” They underscore the importance of considering not only symptoms but also “the factors affecting the patient’s life and their real hopes for treatment.”

Recently, research efforts have focused on finding ways to address resistance, such as developing blood tests that could predict the presence of beta-amyloid in the brain. This advancement could help inform treatment decisions more effectively, allowing for more direct and personalized interventions for patients with neurodegenerative conditions. Moreover, the lack of information and support for patients can significantly contribute to treatment resistance. Examples include insufficient understanding of the condition, stigma associated with mental illnesses, and the impact of social networks on patients’ self-image. Therefore, interventions should include educational and support strategies to improve treatment adherence.

Technology-based interventions, such as monitoring apps and telemedicine, have shown potential to help in this regard. These tools can facilitate ongoing follow-up and encourage patients to report symptoms and side effects in real time, promoting a proactive approach to treatment management.

Integration in Nursing Practices



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)



[10.59087/biofarma.v4i1.35](https://doi.org/10.59087/biofarma.v4i1.35)

Continuous Professional Training

The intricate relationship between pharmacology and neuroscience requires that nursing professionals be highly trained and prepared to handle innovations in treating neurological and psychiatric conditions. Continuing education programs become essential, not only for staying updated on new medications and therapies but also for understanding their implications in clinical practice.

An educational model emphasizing evidence-based practice, critical analysis, and problem-solving can provide nurses with the necessary tools to implement new therapies ethically and effectively. Additionally, including dimensions on drug resistance, management of side effects, and the importance of a holistic approach in patient care may lead to more appropriate care. Interdisciplinary collaboration is another vital component in training healthcare professionals. Nurses must be able to work in teams with pharmacists, psychologists, and other specialists to formulate treatment strategies that consider not only medical aspects but also social and psychological factors influencing patients' health. Effective practice does not limit itself to medication prescription. Nurses play an essential role in observing responses to new therapies, collecting data that may contribute to future research, and helping to shape the overall treatment of Alzheimer's disease and other cognitive conditions.



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)



Holistic and Technological Approaches in Patient Care

The holistic approach, which considers all aspects of a patient's well-being, is increasingly recognized as fundamental in a complex treatment landscape. Patient care should go beyond physical symptoms, including the assessment of emotional, social, and environmental factors that may impact mental and physical health. A study published in *Health Psychology Review* analyzed the impact of social support and family context on mental health, emphasizing that an integrated approach is crucial to promoting the overall well-being of the patient (VanderWeele et al., 2020).

Emerging technologies, such as telemedicine, have shown promise in facilitating continuous communication between patients and healthcare professionals. A study in the *Telemedicine Journal and e-Health* confirmed that using telemedicine services for monitoring mental health conditions significantly improved treatment adherence and reduced symptoms compared to traditional care (Moulaei et al., 2023). This approach allows for more constant monitoring of patient health, enabling early interventions in cases of relapses or adverse side effects.

Moreover, the use of mobile applications can assist in self-care and educate patients about their conditions. Technological tools that enable symptom tracking and communication with healthcare professionals contribute to patient autonomy and may minimize treatment resistance. In light of the rise of psychiatric illnesses, an integrated approach that effectively



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)



utilizes technology promises a more inclusive future, where patients have a leading role in their treatment.

Public Health Policies and Ethical Challenges

Implementation of Therapeutic Innovations

Therapeutic innovations in pharmacology cannot be implemented in isolation; they require robust support through public health policies. The World Health Organization (WHO) emphasizes the importance of clear guidelines that ensure new treatments are introduced safely and efficiently into health systems. Developing policies that promote equity in access and integration of new therapies is vital to ensuring that all individuals, regardless of their socioeconomic context, have the opportunity to benefit from these advancements.

One example of an effective public policy is funding research for innovative medications and subsidies to accelerate their accessibility. Transparency in pricing issues and regulation of drug prices are essential to avoid making innovations available only to high-income populations.

Furthermore, policies must consider the need for ongoing education for healthcare professionals, ensuring they are prepared to apply new practices. The emergence of new research and discoveries about beta-amyloid and its impact on diagnoses and treatments should be included in this training, especially in light of what was discussed by Souza and



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)



Menegucci (2023), where they highlight the importance of laboratory tests for providing a secure diagnosis.

Thus, policies should be directed towards the integrated and multidisciplinary training of healthcare professionals, ensuring that all involved in patient care are aligned with best evidence-based practices.

Ethical Challenges and Access to Treatments

The ethical dilemmas arising from the introduction of new therapies must be seriously addressed. Issues such as unequal access to innovative drugs and the associated costs of therapy are recurring concerns. A study by Piggin et al. (2022) demonstrated that, although a treatment has been licensed for over 10 years, due to its prohibitive cost, only about 25% of countries offer access to it. This situation reflects an alarming disparity in the availability of new therapeutic options. Despite total sales of the top 10 biological medications increasing from \$77 billion to \$82 billion in 2018, there is hope that biosimilars, designed to cost 20% to 30% less than reference biologics, may help reduce prices and thus increase access to essential treatments.

In addition to associated costs, access to accurate diagnostics is often limited, particularly in vulnerable populations or those with reduced access to quality healthcare services.



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)



[10.59087/biofarma.v4i1.35](https://doi.org/10.59087/biofarma.v4i1.35)

Implementing policies that ensure equity in access is crucial in an environment where new diagnostics and treatments continually emerge.

Therefore, it is essential that public health policies not only promote new therapies but also ensure that these innovations are accessible to all. This involves developing subsidy programs, distribution strategies, and awareness campaigns about new treatments. Decisions regarding resource allocation must be guided by principles of equity and justice, emphasizing the need to ensure that all individuals have access to the treatments they require.

Moreover, healthcare professionals should be prepared to discuss ethical issues with their patients, including the risks and benefits associated with new therapies. Open and honest communication can contribute to informed decision-making, allowing patients to feel empowered in their treatment choices.

Outcomes and Discussion

Pharmacological innovations offer hope for treating complex diseases, but challenges arise that require a multidisciplinary and integrated approach. Drug resistance, adverse side effects, and the need for proper continuous education are crucial issues that must be addressed effectively. Integrating technology into patient care can facilitate monitoring and support, improving clinical outcomes and reducing treatment resistance.



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)



[10.59087/biofarma.v4i1.35](https://doi.org/10.59087/biofarma.v4i1.35)

The empirical research presented on beta-amyloid and plans for developing new diagnostic tests and treatments provides a solid foundation for discussion. Recognizing the need for a more precise diagnosis of Alzheimer's disease and existing initiatives are significant steps that may change how the condition is treated and managed in the future. Advancements in diagnostic methodologies and innovation in pharmacological treatments suggest a positive direction, but there is still a long way to go.

The professional training of nurses and other healthcare professionals should be a priority, as should the implementation of public policies promoting equitable access to treatments. Only through ongoing collaboration between science, clinical practice, and health policies will it be possible to ensure that all patients benefit from emerging therapeutic innovations.

Conclusion

In a world where pharmacological innovations and advancements in neuroscience are continually evolving, the adaptation of nursing practices and the strengthening of public health policies are essential. Promoting holistic and integrated care, which recognizes the importance of emotional, social, and psychological support, is crucial for meeting patient needs. As we continue to navigate a future filled with new discoveries, collaboration among all health stakeholders will be vital to ensuring these innovations have a positive impact on patients' lives.



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)



[10.59087/biofarma.v4i1.35](https://doi.org/10.59087/biofarma.v4i1.35)

References

- Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. *Psychiatr Clin North Am.* 1996 Jun;19(2):179-200. [https://doi.org/10.1016/s0193-953x\(05\)70283-5](https://doi.org/10.1016/s0193-953x(05)70283-5) PMID: 8827185.
- Huang HM, Huang CY, Lee-Hsieh J, Cheng SF. Establishing the competences of clinical reasoning for nursing students in Taiwan: From the nurse educators' perspectives. *Nurse Educ Today.* 2018 Jul;66:110-116. <https://doi.org/10.1016/j.nedt.2018.04.007> Epub 2018 Apr 14. PMID: 29702439.
- Khoury R, Patel K, Gold J, Hinds S, Grossberg GT. Recent Progress in the Pharmacotherapy of Alzheimer's Disease. *Drugs Aging.* 2017 Nov;34(11):811-820. <https://doi.org/10.1007/s40266-017-0499-x> PMID: 29116600.
- Leichsenring, F., Abbass, A., Fonagy, P., Levy, K. N., Lillengren, P., Luyten, P., et al. (2024). WHO treatment guideline for mental disorders. *The Lancet Psychiatry*, 11(9), 676-677. [https://doi.org/10.1016/S2215-0366\(24\)00169-X](https://doi.org/10.1016/S2215-0366(24)00169-X)
- Lewczuk, Piotr, et al. "Clinical significance of fluid biomarkers in Alzheimer's Disease." *Pharmacological Reports* 72 (2020): 528-542.
- McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH, Ly-Uson J, Mansur RB, McAllister-Williams RH, Murrugh JW, Nemeroff CB, Nierenberg AA, Rosenblat JD, Sanacora G, Schatzberg AF, Shelton R, Stahl SM, Trivedi MH, Vieta E, Vinberg M, Williams N, Young AH, Maj M. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. *World Psychiatry.* 2023 Oct;22(3):394-412. <https://doi.org/10.1002/wps.21120> PMID: 37713549; PMCID: PMC10503923.
- Moulaei, K., Sheikhtaheri, A., Fatehi, F. et al. Patients' perspectives and preferences toward telemedicine versus in-person visits: a mixed-methods study on 1226 patients. *BMC Med Inform Decis Mak* 23, 261 (2023). <https://doi.org/10.1186/s12911-023-02348-4>
- Pais, M., Martinez, L., Ribeiro, O., Loureiro, J., Fernandez, R., Valiengo, L., Canineu, P., Stella, F., Talib, L., Radanovic, M., & Forlenza, O. V.. (2020). Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. *Brazilian Journal of Psychiatry*, 42(4), 431–441. <https://doi.org/10.1590/1516-4446-2019-0735>
- Piggin, Maria M. Abordando a desigualdade de acesso a produtos biológicos: qual é o seu papel? A perspectiva de um paciente (defensor) sobre biossimilares. *HemaSphere* 6(4):p e702, abril de 2022. | doi.org/10.1136/10.1097/HS9.0000000000000702
- Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O,



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)



Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature*. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323. Update in: *Nature*. 2017 Jun 21;546(7659):564. <https://doi.org/10.1038/nature19323> PMID: 27582220.

Varesi A, Carrara A, Pires VG, Floris V, Pierella E, Savioli G, Prasad S, Esposito C, Ricevuti G, Chirumbolo S, Pascale A. Blood-Based Biomarkers for Alzheimer's Disease Diagnosis and Progression: An Overview. *Cells*. 2022 Apr 17;11(8):1367. <https://doi.org/10.3390/cells11081367> PMID: 35456047; PMCID: PMC9044750.

VanderWeele, T. J., Chen, Y., Long, K., Kim, E. S., Trudel-Fitzgerald, C., & Kubzansky, L. D. (2020). Positive epidemiology?. *Epidemiology*, 31(2), 189-193.

Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. *Pharmacol Rev*. 2018 Jul;70(3):621-660. doi: 10.1124/pr.117.015198. Erratum in: *Pharmacol Rev*. 2018 Oct;70(4):879. <https://doi.org/10.1124/pr.117.015198> PMID: 29945898; PMCID: PMC6020109.



Multidisciplinary Scientific Journal of Biology, Pharmacy and Health

biofarma study center

ISSN Number: (2965-0607)

